Senseonics - SENS STOCK NEWS

Senseonics Holdings, Inc. (NYSE American: SENS) reported its financial results for the quarter ended September 30, 2022, generating $4.6 million in revenue, up from $3.5 million in Q3 2021. U.S. revenue rose to $1.9 million, while international revenue saw a decline to $2.7 million. The company experienced a net loss of $60.4 million compared to a net income of $42.9 million in the previous year, largely due to non-cash accounting adjustments. Senseonics updated its full-year revenue outlook to $15.0 million to $17.0 million from a previous range of $14.0 million to $18.0 million.

Senseonics Holdings, Inc. (SENS) announces its collaboration with the Nurse Practitioner Group (NPG) to enhance access to the Eversense® E3 Continuous Glucose Monitoring (CGM) System. The initiative aims to provide convenient at-home and in-office insertion options for diabetes patients. The first Eversense E3 sensor was successfully inserted in Florida, with plans for expansion across the U.S. This partnership will facilitate certified NPG providers to perform Eversense procedures, thereby broadening clinician reach and improving patient experiences.

Senseonics Holdings, Inc. (NYSE American: SENS) has announced it will release its third quarter 2022 financial results after market close on November 8, 2022. The management will host a conference call at 4:30 p.m. ET on the same day to discuss the company's performance. Senseonics focuses on long-term, implantable continuous glucose monitoring (CGM) systems aimed at the diabetes community, with products like Eversense® and Eversense® XL providing real-time glucose data through a small sensor under the skin.

Senseonics Holdings, Inc. (NYSE American: SENS) announced participation in the upcoming Morgan Stanley Global Healthcare Conference in New York. On October 5, 2022, the company granted 6 non-executive employees stock options for a total of 78,000 shares at an exercise price of $1.34, contingent on continued service and vesting after one year. Senseonics aims to expand its Eversense CGM System availability and enhance the product, which continuously measures glucose levels for up to 6 months, providing an alternative to traditional fingerstick tests.

Senseonics Holdings, Inc. (NYSE American: SENS) announced its participation in the Morgan Stanley Global Healthcare Conference on September 13, 2022, at 7:20 am ET in New York, NY. The event will include one-on-one meetings, and interested parties can access a live and recorded webcast via the company's website at www.senseonics.com. Senseonics specializes in long-term, implantable continuous glucose monitoring systems, aiming to enhance the lives of those with diabetes.

Senseonics Holdings, Inc. (AMEX: SENS) announced the transition of its Chief Financial Officer, Nick Tressler, effective September 1, 2022. Rick Sullivan, the current Vice President of Finance, will succeed Tressler. The company emphasizes Sullivan's proven track record and leadership abilities to enhance operational and financial performance. Tressler will remain with Senseonics in a supporting role until the end of the year. The transition is expected to continue the company's strategic initiatives in the medical technology sector, specifically in long-term glucose monitoring systems.

Senseonics Holdings, Inc. (NYSE American: SENS) plans to present at the Inaugural Gilmartin Group Emerging Showcase virtually on August 31, 2022, at 3:00pm ET. The company specializes in developing long-term, implantable continuous glucose monitoring systems for diabetes management. Interested parties can access a live and archived webcast of the presentation on the company’s website at www.senseonics.com. The Eversense® CGM systems provide real-time glucose data through a small sensor under the skin, enhancing diabetes care.

Senseonics Holdings, Inc. (NYSE American: SENS) reported a revenue of $3.7 million for Q2 2022, up from $3.3 million in Q2 2021. The U.S. revenue increased to $1.2 million from $1.0 million year-over-year. Gross profit improved to $0.8 million, up from $0.4 million. Notably, the company recorded a net income of $104.2 million, attributed to adjustments in embedded derivatives. Senseonics also reaffirmed its full-year revenue guidance of $14.0 million to $18.0 million. Recent highlights included CE mark approval for the E3 system and improved patient access through coverage decisions.

Senseonics Holdings, Inc. (AMEX: SENS) announced that Anthem is providing coverage for its Eversense E3 Continuous Glucose Monitoring (CGM) System, adding over 45 million covered lives. This expands the total coverage for Eversense to approximately 250 million lives in the U.S. The Eversense CGM offers a six-month sensor life, accurate glucose data, and remote monitoring capabilities for diabetes management. The decision follows similar coverage expansions by other major insurers, enhancing the accessibility of this advanced monitoring technology.